Fiberoptic Bronchoscopy & Bronchoalveolar Lavage in Critically Ill

Status Recruiting

Clinical Trial Summary

Fiberoptic bronchoscopy (FOB) is widely used as a diagnostic or therapeutic procedure in intensive care units. Patients with ARDS or COVID-19 disease often undergoes to these procedures. However, intensive care patients might suffer from serious side effects such as prolonged oxygen desaturation and adverse change in lung compliance and resistance. This study aims to evaluate these changes and determine their impact on patient stability.

Clinical Trial Description

Fiberoptic bronchoscopy (FOB) is widely used in intensive care units as a diagnostic or therapeutic procedure. FOB in respiratory failure patients supported by mechanical ventilation may worsen hypoxemia and hypercapnia, therefore FOB requires careful consideration in this patient population. The generally accepted indications for FOB in ventilated patients are removal of retained secretions, resolution of atelectasis and evaluation of hemoptysis. A diagnostic indication is the bronchoalveolar lavage (BAL), to sample the lower respiratory tract without contamination. Studies of FOB performed in mechanically ventilated patients suggest an acceptable safety profile, except for the occurrence of hypoxemia as the main adverse event. Bronchoalveolar Lavage (BAL) in normal volunteers is reported to be safe and does not lead to measurable changes in pulmonary function parameters. However, in intensive care patients may suffer from serious side effects such as prolonged oxygen desaturation. Moreover, reductions in arterial oxygen tension (PaO2) have been reported to persist in some patients for 4 h and more after the procedure. Authors reported the BAL procedure is associated to a worsening of PaO2/FiO2 ratio, in several ARDS patients the drop in PaO2 was higher than 30%. Moreover a physiological study in patients undergoing FOB and BAL showed adverse change in lung compliance and resistance. The purpose of this prospective study is to determine the alterations in respiratory mechanics (regional compliance and resistance) and gas exchange induced by FOB and BAL up to 6 hours after the procedure. The lung regional ventilation evaluation will be made by electrical impedance tomography (EIT). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04502368
Study type	Observational
Source	Erasme University Hospital
Contact	Francesco Ricottilli, MD
Phone	+32(02)5553344
Email	francesco@ricottilli.eu
Status	Recruiting
Phase
Start date	September 1, 2020
Completion date	April 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03376204` - Pain Mechanisms in Patients With Bronchiectasis
Not yet recruiting	`NCT05902702` - Isotonic Saline for Children With Bronchiolitis	N/A
Recruiting	`NCT05246098` - REVIVe: Frailty, Rehabilitation, and Outcomes in Critically Ill Adult and Pediatric Survivors of COVID-19 or ARI
Completed	`NCT04467190` - Investigation of Inflammacheck to Measure Exhaled Breath Condensate Hydrogen Peroxide in Respiratory Conditions
Not yet recruiting	`NCT05374148` - Respiratory Health Problems Among Workers in Ferrosilicon Alloys Industry in Aswan-Eygpt.
Recruiting	`NCT05775952` - Airway Remodeling and Rhinovirus in Asthmatics
Active, not recruiting	`NCT02681848` - What Are the Effects of Varenicline Compared With Nicotine Replacement Therapy on Long Term Smoking Cessation and Clinically Important Outcomes?
Recruiting	`NCT06002685` - Partners in Children's Health (CSN): A Randomized Trial of an Attachment Based Intervention	N/A
Enrolling by invitation	`NCT03319446` - Collection of Anonymized Samples	N/A
Recruiting	`NCT04287959` - SWISH Trial (Strategies for Weaning Infants on Supportive High Flow)	N/A
Completed	`NCT05017727` - Closed-loop Oxygen Control in Ventilated Infants Born at or Near Term
Completed	`NCT04607330` - Protein Top-up Acceptability Study for Patients With Increased Protein Needs	N/A
Completed	`NCT03334916` - A Clinical Trial to Evaluate the Efficacy and Safety of YMC026 in Respiratory Disease Patients	Phase 4
Completed	`NCT04649736` - Home-based Respiratory Physiotherapy and Telephone-Based Psychological Support in Severe COVID-19 Patients	N/A
Completed	`NCT03661801` - Novel Pleural Fluid, Biopsy and Serum Biomarkers for the Investigation of Pleural Effusions
Enrolling by invitation	`NCT03322254` - How Respiratory Pathogens Panel Results Affect Patients' Plan of Care
Recruiting	`NCT03937583` - Screening for Cancer in Patients With Unprovoked VTE	Phase 4
Not yet recruiting	`NCT06026163` - Caffeine as an Adjuvant Therapy for Late Preterm Infants With Respiratory Distress	Phase 2/Phase 3
Completed	`NCT04581096` - Mapping COVID-19 Spread in a Tertiary Hospital
Completed	`NCT03654092` - Home-based Exercise Training for COPD Patients (HOMEX-2)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Fiberoptic Bronchoscopy and Bronchoalveolar Lavage in Critically Ill Ventilated Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms